2 reports

  • 9.3.6.3. CAR-T THERAPY AND RESEARCH LANDSCAPE
  • 9.2.2.3. CAR-T THERAPY AND RESEARCH LANDSCAPE

INTRODUCTION Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of...

  • Motor Vehicle
  • China
  • East Asia
  • Company
  • Celyad SA
  • 02/13/2018: Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers
  • Mar 08, 2017: Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Summary Celyad SA (Celyad), formerly Cardio3 BioSciences, is a clinical-stage biopharmaceutical company that offers discovery and development of engineered cell therapies.The company offers C-Cure, a cell-based reparative therapy to treat heart failure. It offers C-Cathez, an intraventricular injection catheter used...

  • Healthcare
  • Motor Vehicle
  • Pharmaceutical
  • United States
  • Celyad SA